NASDAQ · ANL
Adlai Nortye Ltd.
$10.28+$0.08 (+0.78%)
Adlai Nortye Ltd.’s quoted price sits in the upper half of its reported 52-week range, 40.41% below the high.
Loading market information…
OTC · ADTX · USD
Stock price, earnings
Quote as of Oct 29, 2026, 06:58 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Aditxt, Inc.’s quoted price sits in the lower half of its reported 52-week range, 100.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Aditxt, Inc.’s next earnings report is currently expected on Dec 2, 2026, with estimated earnings per share of -$24,408,000,000.00. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Aditxt, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions. Aditxt also pioneers Apoptotic DNA Immunotherapy, a nucleic acid-based solution that emulates the body's inherent mechanisms for developing self-tolerance to its own tissues. Additionally, Aditxt is actively researching and developing ADi products with diverse therapeutic applications, such as for organ transplant procedures (including skin grafting), various autoimmune conditions, and allergic reactions. The company holds licensing agreements with esteemed institutions like Loma Linda University and Leland Stanford Junior University. Established in 2017, this Richmond, Virginia-headquartered company was initially known as ADiTx Therapeutics, Inc. before rebranding to Aditxt, Inc. in July 2021.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | Apr 14, 2025 | -$10,910,376.00+85.01% vs estimate | $300.00K+120.59% vs estimate |
|---|
| Q3 2024 | Nov 18, 2024 | -$6,822,481.28+30.12% vs estimate | $124.00K-50.4% vs estimate |
|---|
| Q2 2024 | Aug 19, 2024 | -$89,797,032.00+68.17% vs estimate | $221.00K-38.1% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$10.28+$0.08 (+0.78%)
Adlai Nortye Ltd.’s quoted price sits in the upper half of its reported 52-week range, 40.41% below the high.
$3.54+$0.22 (+6.63%)
Tharimmune, Inc.’s quoted price sits in the lower half of its reported 52-week range, 61.01% below the high.
$20.80+$0.83 (+4.16%)
Apollomics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.48% below the high.
$6.75-$0.44 (-6.12%)
Athira Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 19.26% below the high.
$0.56+$0.02 (+4.07%)
Citius Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 65.45% below the high.
₪0.01₪0.00 (0.0%)
BioLineRx Ltd.’s quoted price sits in the lower half of its reported 52-week range, 47.62% below the high.
$8.72-$0.03 (-0.29%)
Moleculin Biotech, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.23% below the high.
$2.31-$0.17 (-6.85%)
SeaStar Medical Holding Corporation’s quoted price sits in the lower half of its reported 52-week range, 61.5% below the high.
